| Market Cap | $260.55M-30.8% |
| Revenue (ttm) | $4.78M |
| Net Income | -$65.36M |
| EPS | -$0.20 |
| Shares Out | 339.31M |
| PE Ratio | n/a |
| Forward PE | -4.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,186,721 |
| Open | $0.71 |
| Previous Close | $0.73 |
| Day's Range | $0.71 - $0.82 |
| 52-Week Range | $0.69 - $2.73 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | $12.17(+1484.41%) |
| Earnings Date | Nov 4, 2026 |
About OCGN
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating OCGN in the last 3 months, one vote each. Issuer-paid research is not counted.
$OCGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in OCGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OCGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OCGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OCGN Revenue by Segment
| Change in fair value of derivative liability | $16.56M | 84.27% |
| Collaborative Arrangements | $1.95M | 9.93% |
| Facilities and other support costs | $837.00K | 4.26% |
| Other | $303.00K | 1.54% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OCGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OCGN from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from OCGN’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 12Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| MOON | Direxion Moonshot Innovators ETF | 2.12% |
| GERM | ETFMG Treatments, Testing and Advancements ETF | 0.76% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 0.28% |
| XDNA.TO | iShares Genomics Immunology and Healthcare Index ETF CAD | 0.24% |
| XBI | State Street SPDR S&P Biotech ETF | 0.10% |
| IWC | iShares Micro-Cap ETF | 0.08% |
| KOMP | State Street SPDR S&P Kensho New Economies Composite ETF | 0.07% |
| PWS | Pacer WealthShield ETF | 0.02% |
| LABU | Direxion Daily S&P Biotech Bull 3X Shares | 0.02% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
